Cyclacel Price To Book Ratio from 2010 to 2024
| CYCC Stock | USD 0.41 0.06 17.14% |
Price To Book Ratio | First Reported 2010-12-31 | Previous Quarter 3.74246466 | Current Value 3.93 | Quarterly Volatility 79.59156182 |
Check Cyclacel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclacel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 29.4 K, Interest Expense of 2.4 M or Selling General Administrative of 5.9 M, as well as many indicators such as Price To Sales Ratio of 5.91, Dividend Yield of 0.0929 or PTB Ratio of 3.93. Cyclacel financial statements analysis is a perfect complement when working with Cyclacel Pharmaceuticals Valuation or Volatility modules.
Cyclacel | Price To Book Ratio |
Latest Cyclacel Pharmaceuticals' Price To Book Ratio Growth Pattern
Below is the plot of the Price To Book Ratio of Cyclacel Pharmaceuticals over the last few years. It is a ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share. Cyclacel Pharmaceuticals' Price To Book Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclacel Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Price To Book Ratio | 10 Years Trend |
|
Price To Book Ratio |
| Timeline |
Cyclacel Price To Book Ratio Regression Statistics
| Arithmetic Mean | (6.47) | |
| Coefficient Of Variation | (1,230) | |
| Mean Deviation | 37.47 | |
| Median | 7.19 | |
| Standard Deviation | 79.59 | |
| Sample Variance | 6,335 | |
| Range | 353 | |
| R-Value | 0.28 | |
| Mean Square Error | 6,276 | |
| R-Squared | 0.08 | |
| Significance | 0.31 | |
| Slope | 5.04 | |
| Total Sum of Squares | 88,687 |
Cyclacel Price To Book Ratio History
About Cyclacel Pharmaceuticals Financial Statements
Cyclacel Pharmaceuticals stakeholders use historical fundamental indicators, such as Cyclacel Pharmaceuticals' Price To Book Ratio, to determine how well the company is positioned to perform in the future. Although Cyclacel Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cyclacel Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Cyclacel Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cyclacel Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Price To Book Ratio | 3.74 | 3.93 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:Check out the analysis of Cyclacel Pharmaceuticals Correlation against competitors. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.40) | Revenue Per Share 0.044 | Quarterly Revenue Growth (0.99) | Return On Assets (1.03) | Return On Equity (5.71) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.